Jun 01, 2021 / 07:00PM GMT
Dingding Shi - Jefferies LLC, Research Division - Equity Analyst
Good afternoon, everyone. My name is Kelly Shi, one of the biotech equity analyst at Jefferies. Thank you for attending our virtual health care conference. We are very pleased to have Dr. Zang Jingwu, Founder and Director of I-Mab Biopharma joining us today for this fireside chat.
I-Mab has made a tremendous progress since the IPO in early 2020, among which the first data from CD47 antibody and AbbVie partnership as well as the ASCO update of their CD73 combo have attracted great attention from investors. But [for not] missing a broad pipeline outside of these 2 IO candidates, I think we're going to start out with Dr. Zang give us an overview for I-Mab, what the milestones that company has made since the IPO, and what are the key learnings so far. Dr. Zang?
Jingwu Zhang Zang - I-Mab - Founder, Honorary Chairman & Director
Thank you, Kelly. We have made remarkable progress in those 3 areas of business. The first area where major progress is made is related to the pipeline development.
I-Mab at Jefferies Healthcare Conference (Virtual) Transcript
Jun 02, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers